fda semaglutide shortage list ends as sets deadline for compounders FDA crackdown on off-brand Ozempic

In 2024, the category doubled in size following the launch of Wegovy (semaglutide) in [] An article on how legislative changes in Alberta are impacting employer-sponsored benefits plans was the most-read article on BenefitsCanada.com this past week

GLP-1 Side Chains Peptide Intermediates Fmoc-His-Aib-OH Fmoc-Ile-Aib-OH Fmoc-Tyr(tBu)-Aib-OH Fmoc-Glu(OtBu)-Aib-OH Fmoc-His(Fmoc)-Aib-OH Fmoc-His(Fmoc)-Aib-OSu Tirzepatide Fragments CAS:2682040-93-1 CAS:3034670-52-2 CAS:2656383-23-0 CAS:2461524-68-3 CAS:2656383-24-1 CAS:2656383-25-2 API & Excipients Cosmetic Peptides Oligopeptide-1 NonaPeptide-1 Copper Tripeptide-1 Acetyl Hexapeptide-8 Palmitoyl Tripeptide-1 Decarboxy Carnosine HCl Active Ingredients Number: CG-CPT-004 CAS: 147732-56-7 INCI: Palmitoyl Tripeptide-1Tocophersolan Specification: Powder 100ppm Appearance: White to slightly yellow powder / Colorless to pale yellow liquid Solubility: Powder: Alcohol-soluble

Amyotrophic lateral sclerosis

Studies in ovariectomized mice showed that estrogen replacement increased GLP-1 release from both intestinal L-cells and pancreatic alpha-cells